TFF Pharmaceuticals announced the Cleveland Clinic Florida will perform additional preclinical studies of 3 dry powder hemagglutinin antigen/adjuvent vaccine candidates produced under a 2023 SBIR grant to TFF for preclinical development of a dry powder pan-influenza vaccine formulation for inhaled and/or nasal delivery. The vaccine developed in Ted Ross’s lab at the Cleveland Clinic has been formulated with several different adjuvants using TFF’s thin film freezing technology.
Ross commented, “Over the last year, we have generated an impressive body of positive in vitro and in vivo data from these experimental influenza vaccines, enabling us to further advance these promising candidates into additional in vivo preclinical efficacy studies. Our team at Cleveland Clinic looks forward to advancing this important research, which brings us one step closer toward developing a universal influenza vaccine with the potential to protect patients worldwide.”
TFF Pharmaceuticals CEO Harlan Weisman said, “Working in collaboration with Dr. Ted M. Ross and his colleagues, our goal is to develop a shelf-stable mucosal vaccine with unique characteristics for inhalational delivery and would circumvent the need for cold chain storage which could significantly improve the availability and distribution of potentially life-saving medicine. We look forward to advancing these vaccine candidates into preclinical studies formulated with our thin film freezing technology.”
Read the TFF Pharmaceuticals press release.
